Pancreatic Cancer: Basic Mechanisms and Therapies - Couverture rigide

Couverture rigide

ISBN 10 : 0443133549 ISBN 13 : 9780443133541

Editeur : Academic Press Inc, 2023

Synopsis

Pancreatic Cancer: Basic Mechanisms and Therapies, Volume 159 in the Advances in Cancer Research, presents the latest release in this ongoing, well-regarded serial with invaluable information on the exciting and fast-moving field of cancer research.

Pancreatic cancer (PC) is the third leading cause of cancer-related deaths in the United States. Greater than 90% PCs are Pancreatic ductal adenocarcinomas (PDAC) which have a dismal estimated 5-year overall survival of only 11%. PDAC is predicted to become the second leading cause of mortality in the United States by 2030. In the clinic, the PDAC patients often present with incurable disease at the time of first diagnosis. This cancer is particularly lethal because of its propensity to spread quickly to distant organs including the lymphatic system. PDAC metastasis occurs shortly after tumor initiation and is caused by a complex interaction between autonomous tumor cells and cellular elements of the tumor microenvironment. Although PDAC remains a challenging disease to treat and a leading cause of cancer-related deaths, progress is being made in disease etiology and pathogenesis, and intensive research is focused on developing optimal treatment approaches for patients. Considering the continuous progress being made in understanding PDAC pathogenesis and designing new therapies, it was considered timely to develop an up-to-date thematic issue of Advances in Cancer Research (ACR) focused on PDAC.

In this thematic issue, we have included ten review articles by experts that cover cancer disparities, PDAC pathobiology, the roles of the tumor microenvironment, tumor heterogeneity, PC stem cells, genetic and signaling events critical for PDAC pathogenesis, Immunotherapy and chemoresistance in PDAC, and different PDAC mouse models. This special issue highlights recent research progress in PDAC, which bridges the gap between basic and clinical research.

A propos du livre

À propos des auteurs

Luni Emdad, PhD, MBBS received her PhD degree in Medical Science from the Nagoya University Graduate School of Medicine and her Bachelor degree in Medicine and Surgery (MBBS) from Dhaka Medical college. After completing her Postdoctoral training in the department of Pathology and Urology with Dr. Paul B. Fisher at the Columbia University, she remained as Associate Research Scientist at the Columbia University until Dec 2007. From 2008-2011, she served as Assistant Professor, Department of Neurosurgery, Mount Sinai School of Medicine, New York. In 2011, she joined the Department of Human and Molecular Genetics, Virginia Commonwealth University as an Assistant professor. In 2020, she was promoted to Associate professor at Virginia Commonwealth University. Dr. Emdad is a scientist with a clinical background (dual degree of Bachelors of Medicine and Surgery and Ph.D.) and has a longstanding research experience in cancer research with in depth molecular knowledge in targeted experimental therapeutics development for cancer.

She has published over 150 in journals such as Proceedings of the National Academy of Science USA, Cancer Research, Journal of Clinical Investigation, Hepatology, Oncogene, Semin Cancer Biol, Neuro-Oncology and so on. She has served as principal investigator in two sponsored research programs and an inventor in two issued US patents.

Dr. Azeddine Atfi is the leader of Cancer Biology Program at NCI-designated Massey Cancer Center. He is also the Professor and Chair of
the Cellular and Molecular Pathogenesis Division at the Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA.

Dr. Rajan Gogna is an assistant professor at the School of Medicine Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.

Dr. Jose Trevino is an associate professor at the Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA.

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics") of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Détails de l'édition

• Éditeur: Academic Press Inc
• Date d'édition: 2023
• Langue: anglais
• ISBN 10: 0443133549
• ISBN 13: 9780443133541
• Reliure: Relié
• Nombre de pages: 390
• Éditeur: Emdad Luni, Atfi Azeddine, Gogna Rajan, Trevino Jose G, Fisher Paul B.
• Coordonnées du fabricant: non disponible
• Personne responsable: Yeepin GmbH; 492000000000; sunshine12232@outlook.com; ; Alleestr.11; Kaiserslautern; Rheinland-Pfalz; 67655; Allemagne